Identification of novel targets in the treatment of lung cancer
Project/Area Number |
26293318
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory surgery
|
Research Institution | Okayama University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
豊岡 伸一 岡山大学, 医歯(薬)学総合研究科, 教授 (30397880)
宗 淳一 岡山大学, 大学病院, 講師 (90559890)
山本 寛斉 岡山大学, 大学病院, 助教 (40467733)
佃 和憲 岡山大学, 大学病院, 講師 (20346430)
阪口 政清 岡山大学, 医歯(薬)学総合研究科, 准教授 (70379840)
片山 博志 岡山大学, 医歯(薬)学総合研究科, 准教授 (90713975)
|
Research Collaborator |
SHIEN Kazuhiko
SUZAWA Ken
OHTSUKA Tomoaki
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2016: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2014: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
Keywords | 肺癌 / HER2 / 遺伝子変異 / チロシンキナーゼ阻害剤 / 癌 / 外科 |
Outline of Final Research Achievements |
Recent developments in the genomic characterization of tumors have contributed to novel therapeutic approaches, and some molecular-targeted therapies based on the genetic profiles of tumors have improved patient survival. Human epidermal growth factor 2 (HER2) is a member of the HER family containing four receptor tyrosine kinases. Recently, we have identified novel mutations in the transmembrane domain of HER2 in lung adenocarcinomas. In this study, we clarified that these mutations could be oncogenic alterations of lung cancer. We also investigated the efficacy of afatinib as a HER2-targeted therapy in these HER2 altered lung cancer cells. In addition, we clarified a novel HER2 binding protein cytokeratin 19 (KRT19), and investigated the impact of KRT19 and HER2 interactions in signal transduction pathways to decode their possible roles in oncogenesis.
|
Report
(4 results)
Research Products
(9 results)
-
[Journal Article] Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.2016
Author(s)
Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, Hashida S, Miyata-Takata T, Watanabe M, Suzawa K, Soh J, Youyi C, Sato H, Namba K, Torigoe H, Tsukuda K, Yoshino T, Miyoshi S, Toyooka S.
-
Journal Title
Sci Rep.
Volume: 6
Issue: 1
Pages: 39557-39557
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations2016
Author(s)
Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, Mizuki Morita, Hiromasa Yamamoto, Shuta Tomida, Tomoaki Ohtsuka, Mototsugu Watanabe, Shinsuke Hashida, Yuho Maki, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda and Shinichiro Miyoshi
-
Journal Title
Cancer Science
Volume: 107
Issue: 1
Pages: 45-52
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Presentation] Cytokeratin 19 binds to HER2 and activates HER2 and its downstream signaling2016
Author(s)
Tomoaki Ohtsuka, Masakiyo Sakaguchi, Shuta Tomida, Hiromasa Yamamoto, Katsuyoshi Takata, Shinsuke Hashida, Mototsugu Watanabe, Ken Suzawa, Yuho Maki, Junichi Soh, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka
Organizer
Tenth AACR-JCA Joint Conference on Breakthroughs in Cancer Research: From Biology to Therapeutics
Place of Presentation
Maui, Hawaii, USA
Year and Date
2016-02-16
Related Report
Int'l Joint Research
-
-
[Presentation] Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene2015
Author(s)
Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, Tomoaki Ohtsuka, Mototsugu Watanabe, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi
Organizer
AACR Annual Meeting 2015
Place of Presentation
Philadelphia, PA, USA
Year and Date
2015-04-18 – 2015-04-22
Related Report
-
[Presentation] Identification of a novel binding protein playing a critical role in HER2 activation in lung cancer cells2015
Author(s)
Tomoaki Ohtsuka, Masakiyo Sakaguchi, Katsuyoshi Takata, Shinsuke Hashida, Mototsugu Watanabe, Ken Suzawa, Yuho Maki, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka
Organizer
AACR Annual Meeting 2015
Place of Presentation
Philadelphia, USA
Year and Date
2015-04-18
Related Report
Int'l Joint Research
-
[Presentation] Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene2015
Author(s)
Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, Tomoaki Ohtsuka, Mototsugu Watanabe, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi
Organizer
AACR Annual Meeting 2015
Place of Presentation
Philadelphia, USA
Year and Date
2015-04-18
Related Report
Int'l Joint Research
-